Home
World Journal of Biology Pharmacy and Health Sciences
ISSN Approved | International, Peer reviewed, Referred, Open access Journal

Main navigation

  • Home
    • Journal Information
    • Abstracting and Indexing
    • Editorial Board Members
    • Reviewer Panel
    • Journal Policies
    • WJBPHS CrossMark Policy
    • Publication Ethics
    • Current Issue
    • Issue in Progress
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Become a Reviewer panel member
    • Join as Editorial Board Member
  • Contact us
  • Downloads

ISSN Approved Journal | | IMPACT FACTOR 8.16 | | eISSN: 2582-5542 | |  Free Crossref DOI 

Fast Publication within 2 days | | Low Article Processing Charges | | Peer Reviewed and Referred Journal

Research and review articles are invited for publication in September 2026 (Volume 27, Issue 3) Submit Paper

Von Willebrand disease in a neonate: A case report

Breadcrumb

  • Home
  • Von Willebrand disease in a neonate: A case report

Imane ZIZI *, Ilham ELOUARDIGHI, Najat AMALIK, Lamiae ELIAZIJI, Houria KENOUNI and Amina BARKAT

Department of neonatology, Children's hospital of Rabat, Morocco. Faculty of medicine and pharmacy, University Mohammed V, Rabat, Morocco.

Research Article
 
World Journal of Biology Pharmacy and Health Sciences, 2023, 14(01), 135–137.
Article DOI: 10.30574/wjbphs.2023.14.1.0185
DOI url: https://doi.org/10.30574/wjbphs.2023.14.1.0185

Received on 08 March 2023; revised on 15 April 2023; accepted on 18 April 2023

Von Willebrand disease (VWD) is a constitutional bleeding disorder of autosomal inheritance characterized by a quantitative or functional abnormality of the factor Willebrand. We report the observation of a neonate with a confirmed diagnosis of von Willebrand disease in the neonatal period.
This disease is a very heterogeneous clinically, phenotypically and genetically, and poses a diagnostic difficulty. The biological diagnosis is based on first-line tests (prothrombin level and activated partial thromboplastin time) completed by the measurement of the coagulant activity of factors VIII, IX and XI, as well as the activity and antigen of Von Willebrand factor (VWF). The treatment strategy for VWD should be considered in collaboration with a hematologist aiming to correcting VWF and factor VIII levels. Therefore, a recombinant VWF concentrate has recently been introduced and has proven to be effective.

Coagulation; Hemorrhage; Hemostasis; Platelets

https://wjbphs.com/sites/default/files/fulltext_pdf/WJBPHS-2023-0185.pdf

Get Your e Certificate of Publication using below link

Download Certificate

Preview Article PDF

Imane ZIZI, Ilham ELOUARDIGHI, Najat AMALIK, Lamiae ELIAZIJI, Houria KENOUNI and Amina BARKAT. World Journal of Biology Pharmacy and Health Sciences, 2023, 14(01), 135–137. Article DOI: https://doi.org/10.30574/wjbphs.2023.14.1.0185

Get Certificates

Get Publication Certificate

Download LoA

Check Corssref DOI details

Issue details

Issue Cover Page

Editorial Board

Table of content


Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.


Copyright © 2026 World Journal of Biology Pharmacy and Health Sciences (WJBPHS) - All rights reserved

Developed & Designed by VS Infosolution